Table 2. Differentially methylated loci in ovarian and endometrial cancer and human cell lines.
Probe | Gene | CpG locus (hg19) | Normal | Cancer | P value |
---|---|---|---|---|---|
cg21790626 | ZNF154 | chr19:58 220 494 | 0.18 | 0.94 | 3.11e-08 |
cg16869108 | VHL | chr3:10 184 319 | 0.82 | 0.46 | 4.76e-02 |
cg25391023 | BTNL2 | chr6:32 374 754 | 0.53 | 0.08 | 1.37e-04 |
cg13897627 | FLJ44674 | chr16:49 378 497 | 0.59 | 0.09 | 4.19e-04 |
cg07014174 | KRTAP11–1 | chr21:32 253 760 | 0.60 | 0.07 | 1.59e-05 |
cg20312687 | DEFB118 | chr20:29 956 585 | 0.70 | 0.07 | 1.38e-05 |
cg26799474 | CASP8 | chr2:202 098 951 | 0.89 | 0.16 | 1.63e-04 |
The set of genomic loci that are differentially methylated in serous vs. controls, endometrioid vs. controls and also in cancer vs. normal cell lines from ENCODE. Columns show median methylation (β values) in cell lines labeled as normal and cancer. P values were computed using a two-sided Wilcoxon rank-sum test and adjusted using Holm’s correction for multiple hypotheses (for the 12 candidate probes shown in Table 1). Rows were ordered in decreasing order of difference between median in cancer minus median in normals.